Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/10944
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
Identifiers
DOI: 10.1038/leu.2017.58
ISSN: 0887-6924
eISSN: 1476-5551
WOS ID: 000402832700025
Scopus EID: 2-s2.0-85014659967
PMID: 28210002
Embase PUI: L614736600
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordAuthor
Martinez-Lopez, J.; Sanchez-Vega, B.; Barrio, S.; Cuenca, I.; Ruiz-Heredia, Y.; Alonso, R.; Rapado, I.; Marin, C.; Cedena, M-T; Paiva, B.; Puig, N.; Mateos, M-V; Ayala, R.; Hernandez, M-T; Jimenez, C.; Rosinol, L.; Martinez, R.; Teruel, A-I; Gutierrez, N.; Martin-Ramos, M-L; Oriol, A.; Bargay Lleonart, Joan

Publication date
2017-06Document type
letter to the editorCitation
Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma [letter]. Leukemia. 2017 Jun;31(6):1446-9. Epub 2017 Feb 17.Publisher version
https://dx.doi.org/10.1038/leu.2017.58MeSH
AgedMale
Monitoring, Physiologic
Multiple Myeloma
Neoplasm, Residual
Female
High-Throughput Nucleotide Sequencing
Humans
Survival Analysis
Antineoplastic Combined Chemotherapy Protocols
DeCS
HumanosProtocolos de Quimioterapia Combinada Antineoplásica
Análisis de Supervivencia
Anciano
Monitoreo Fisiológico
Mieloma Múltiple
Femenino
Secuenciación de Nucleótidos de Alto Rendimiento
Neoplasia Residual
Masculino
This item appears in following Docusalut collections
Instituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científicaHospital Universitario Son Llàtzer - HUSLL > Comunicación científica